CCL21

Sherven Sharma; Minu K. Srivastava; Marni Harris White; Dorthe Schaue; Maie St John; Gang Zhang; Percy Lee; Jay M. Lee; Steven Dubinett

doi:10.1007/978-1-4419-0717-2_33

CCL21

Sherven Sharma
, Minu K. Srivastava
, Marni Harris White
, Dorthe Schaue
, Maie St John
, Gang Zhang
, Percy Lee
, Jay M. Lee
, Steven Dubinett

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Chemokines that attract both dendritic cells (DC) and lymphocyte effectors can aid in cancer immunotherapy by enlisting host immune cells to recognize tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment. modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.

Original language	English (US)
Title of host publication	Cancer Therapeutic Targets
Publisher	Springer New York
Pages	111-116
Number of pages	6
Volume	1-2
ISBN (Electronic)	9781441907172
ISBN (Print)	9781441907165
DOIs	https://doi.org/10.1007/978-1-4419-0717-2_33
State	Published - Jan 1 2017
Externally published	Yes

Keywords

Anti-tumor immune activity
CCL21
Chemokine
Dendritic cells
Immune activation
Lung cancer
Tlymphocytes

ASJC Scopus subject areas

General Medicine
General Biochemistry, Genetics and Molecular Biology
General Pharmacology, Toxicology and Pharmaceutics

Access to Document

10.1007/978-1-4419-0717-2_33

Cite this

@inbook{02eea36019ca4ed08548a5ffb44fc76f,

title = "CCL21",

abstract = "Chemokines that attract both dendritic cells (DC) and lymphocyte effectors can aid in cancer immunotherapy by enlisting host immune cells to recognize tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment. modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.",

keywords = "Anti-tumor immune activity, CCL21, Chemokine, Dendritic cells, Immune activation, Lung cancer, Tlymphocytes",

author = "Sherven Sharma and Srivastava, \{Minu K.\} and White, \{Marni Harris\} and Dorthe Schaue and John, \{Maie St\} and Gang Zhang and Percy Lee and Lee, \{Jay M.\} and Steven Dubinett",

year = "2017",

month = jan,

day = "1",

doi = "10.1007/978-1-4419-0717-2\_33",

language = "English (US)",

isbn = "9781441907165",

volume = "1-2",

pages = "111--116",

booktitle = "Cancer Therapeutic Targets",

publisher = "Springer New York",

}

TY - CHAP

T1 - CCL21

AU - Sharma, Sherven

AU - Srivastava, Minu K.

AU - White, Marni Harris

AU - Schaue, Dorthe

AU - John, Maie St

AU - Zhang, Gang

AU - Lee, Percy

AU - Lee, Jay M.

AU - Dubinett, Steven

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Chemokines that attract both dendritic cells (DC) and lymphocyte effectors can aid in cancer immunotherapy by enlisting host immune cells to recognize tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment. modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.

AB - Chemokines that attract both dendritic cells (DC) and lymphocyte effectors can aid in cancer immunotherapy by enlisting host immune cells to recognize tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment. modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.

KW - Anti-tumor immune activity

KW - CCL21

KW - Chemokine

KW - Dendritic cells

KW - Immune activation

KW - Lung cancer

KW - Tlymphocytes

UR - https://www.scopus.com/pages/publications/85038901661

UR - https://www.scopus.com/pages/publications/85038901661#tab=citedBy

U2 - 10.1007/978-1-4419-0717-2_33

DO - 10.1007/978-1-4419-0717-2_33

M3 - Chapter

AN - SCOPUS:85038901661

SN - 9781441907165

VL - 1-2

SP - 111

EP - 116

BT - Cancer Therapeutic Targets

PB - Springer New York

ER -

CCL21

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this